<DOC>
	<DOCNO>NCT02159573</DOCNO>
	<brief_summary>The primary objective study evaluate relapse activity , measure proportion participant relapse 12 month , participant relapsing-remitting multiple sclerosis ( RRMS ) transition Tysabri ( BG00002 ) Tecfidera ( BG00012 ) real-world setting . The secondary objective evaluate relapse activity , define annualized relapse rate ( ARR ) , hospitalization intravenous corticosteroid use , first year Tecfidera treatment follow transition Tysabri treatment .</brief_summary>
	<brief_title>Real-world Outcomes Tecfidera ( BG00012 , Dimethyl Fumarate ) Post-Tysabri ( BG00002 , Natalizumab )</brief_title>
	<detailed_description>The study period consist single time point retrospective medical chart abstraction require study visit procedure . Data collection study expect last approximately five month .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Key Diagnosis RRMS per McDonald criterion Received least 12 month continuous treatment Tysabri monotherapy prior initiation Tecfidera . Note : continuous treatment Tysabri define treatment uninterrupted diseasemodifying treatment . Initiated treatment Tecfidera least 12 month prior enrollment study Patient sufficient available medical record data abstraction meet objective study Key Diagnosed progressive form multiple sclerosis ( MS ) ( progressiverelapsing , primary progressive , secondary progressive ) Received treatment follow discontinuation Tysabri initiation treatment Tecfidera ( i.e. , washout period ) : interferonbeta , glatiramer acetate , fingolimod , teriflunomide , rituximab , alemtuzumab , ocrelizumab investigational compound treatment RRMS Received BG00012 , formulation dimethyl fumarate , FumadermÂ® compound fumarates time prior initiation treatment Tecfidera History progressive multifocal leukoencephalopathy ( PML ) Tysabri within 6 month discontinue treatment Tysabri NOTE : Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>